Literature DB >> 33434512

Lorlatinib in ALK-Rearranged Lung Cancer.

Shelley Kuang1, Natasha B Leighl2.   

Abstract

Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with crizotinib as initial therapy in patients with advanced ALK-rearranged NSCLC.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Year:  2021        PMID： 33434512     DOI： 10.1016/j.ccell.2020.12.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  3 in total

1.  Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions.

Authors:  Yinghuan Dai; Ping Liu; Wenlong He; Lizhen Yang; Yang Ni; Xuejiao Ma; Furong Du; Chao Song; Yang Liu; Yi Sun
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

2.  Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.

Authors:  Kehai Lin; Jie Lin; Zhong Huang; Jiding Fu; Qi Yi; Jiazuo Cai; Muhammad Khan; Yawei Yuan; Junguo Bu
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

3.  Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion.

Authors:  Yingying Pan; Wenjing Xiao; Feng Ye; Huijuan Wang; Yihong Shen; Xinmin Yu; Xiao Han; Qian Chu; Caicun Zhou; Zhihong Zhang; Shengxiang Ren
Journal:  Ann Transl Med       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.